Ep. 43: Running regulatory and clinical operations in an AI world
The Latest Dose
by oraclehealthsciences
3M ago
Artificially intelligent tools are revolutionizing nearly every stage of the drug discovery process, offering substantial potential to reshape the speed and economics of the industry. As the drug discovery and preclinical stages speed up and potentially produce more drugs to test in the clinical trial phase, how do clinical researchers prepare and respond to these challenging opportunities?   In this episode, Toban Zolman, Chief Executive Officer at Kivo will share his thoughts on how AI-enabled successes in drug discovery will affect clinical operations and regulatory operations. We will ..read more
Visit website
Ep. 42: Creating drugs at the speed of AI
The Latest Dose
by oraclehealthsciences
4M ago
Artificial intelligence (AI) is one of the most discussed technologies across all industries. Life science professionals working in the pharmaceutical industry strive to improve people’s lives tackling incredibly complex diseases. Drug development is often perceived as slow. As the pharma industry looks to improve the drug development process AI promises nothing less than a revolution.   Can AI help speed up the drug development process? Identify new drug molecules that have so far eluded scientists?   Will AI–designed medicines be safe for people? Have the desired effect on the dise ..read more
Visit website
Ep. 41: CancerX: Reducing incidence, burden, and disparities in cancer care
The Latest Dose
by oraclehealthsciences
5M ago
Cancer is a leading cause of death worldwide, accounting for nearly 10 million deaths in 2020. President Biden has reignited the Cancer Moonshot initiative and set a new national goal: “if we work together, we can cut the death rate from cancer by at least 50% over the next 25 years and improve the experience of people and their families living with and surviving cancer”. “To achieve [the cancer moonshot goals], we must amplify digital innovation,” stated Dr. Catharine Young, Assistant Director of Cancer Moonshot Engagement and Policy, White House Office of Science and Technology.   Cance ..read more
Visit website
Ep. 40: CancerX: Breaking down the barriers to digital innovation use in oncology
The Latest Dose
by oraclehealthsciences
6M ago
The US cancer death rate has fallen by 33% since 1991 with an estimated 3.8 million deaths averted. This is attributed to “good progress” improvements in cancer treatment, decreases in smoking, and increases in early detection. A recent rise in advanced cancer cases reported is believed to be an outcome of the COVID-19 pandemic which delayed screenings and treatment.   Access, equity, and inclusion when developing and deploying new solutions to combat this disease remain paramount. The impact of cancer on people’s lives and their families is profound. Many live with cancer for long period ..read more
Visit website
Recruiting and retaining experienced principal investigators
The Latest Dose
by oraclehealthsciences
8M ago
The success or failure of clinical trials is dependent in large part on the engagement of the principal investigator (PI). PIs play an important role in trial selection, site activation, and study execution. This includes but is not limited to, the development and implementation of a strategy to maximize enrollment, optimize data quality, and ensure patient retention. The legal, regulatory, financial, and workload burden for site PIs has grown considerably over time. The benefits of serving as a site PI are becoming less evident. As a result, increasing dissatisfaction exists among physicians ..read more
Visit website
Ep. 38: Psychological aspects of clinical trials
The Latest Dose
by oraclehealthsciences
9M ago
Researchers use controls to help them understand what effect a new therapy or drug might have on a particular condition.   Clinical research practice favors placebo controls over usual-care controls. Sometimes a person can have a response, positive or negative, to the placebo control. These responses are known as the "placebo effect and nocebo effect”. The placebo effect demonstrates how positive thinking can improve treatment outcomes. Likewise, the nocebo effect suggests that negative thinking may have the opposite effect. But is this information impacting reported outcomes?   In t ..read more
Visit website
Ep. 37: Digital transformation: empowering or encumbering for research sites?
The Latest Dose
by oraclehealthsciences
10M ago
Clinical research professionals across all types of research organizations often struggled with implementing process improvements and the adoption of digital tools. When external factors (such as pandemic disruptions) force transformational process changes, the adoption of digital tools follows. At that point, the value of the new solutions suddenly becomes stunningly clear.   Patients and research sponsors continue to push for faster, more responsive, and more inclusive drug development. This enables new technologies and solutions to emerge to help meet those expectations. The clinical r ..read more
Visit website
Ep. 36: Digital predictions for clinical research in 2023
The Latest Dose
by oraclehealthsciences
11M ago
Clinical research can make all the difference when it comes to saving people’s lives or improving their quality of life. In this episode, Mathias Eichler-Mertens, Managing Director of Accenture Life Sciences R&D Europe, and Henry McNamara SVP and GM of Oracle Health Sciences, will discuss what can be done to boost innovation and productivity in the year ahead. Hear how to speed up clinical development, contain costs and generate the evidence needed to obtain regulatory approval for new medicines ..read more
Visit website
Ep. 35: Converting to a patient-centric care model
The Latest Dose
by oraclehealthsciences
1y ago
The digital health ecosystem has helped create an infrastructure that supports the transformation of the organization-centered care model into a patient-centered care model. Various reports highlight the staggering investments and the market growth in digital health technologies supporting this change. In this episode of the Latest Dose, Naomi Fried, PhD, Founder & CEO of PharmStars and Steve Prewitt, SVP, Global Head of Digital Innovation at Sumitovant Biopharma, share the importance and significance of new entrants into the market. They discuss how digital health start-ups will power a p ..read more
Visit website
Ep. 33: A leap forward in safety
The Latest Dose
by oraclehealthsciences
1y ago
"First, do no harm" is a popular saying amongst those involved in the healthcare, medicine, or bioethics field, and is a basic principle taught in health-related courses. To faithfully follow this principle, a health professional should help their patients by recommending tests or treatments for which the potential benefits outweigh the risks of harm. In this episode, Michael Fronstin, Global Head of Clinical Regulatory & Safety Research and Consulting and Susanne Faber, Director, Advanced Methodologies Clinical Regulatory & Safety, both from Cerner Enviza, share the value and importan ..read more
Visit website

Follow The Latest Dose on FeedSpot

Continue with Google
Continue with Apple
OR